Abbreviated New Drug Application process

E642120

drug approval process regulatory approval pathway

The Abbreviated New Drug Application process is the U.S. regulatory pathway that allows generic drug manufacturers to gain FDA approval by demonstrating bioequivalence to an already approved brand-name drug without repeating full clinical trials.

Try in SPARQL Jump to: Surface forms Disambiguation Statements Elicitation Referenced by

All labels observed (3)

Label	Occurrences
Abbreviated New Drug Application	4
Abbreviated New Drug Application process canonical	1
Abbreviated New Drug Applications	1

How this entity was disambiguated

This entity first appeared as the object of triple T7110943 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.

NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07

Target entity: Abbreviated New Drug Application process
Context triple: [Drug Price Competition and Patent Term Restoration Act of 1984, establishes, Abbreviated New Drug Application process]

A. FDA traditional approval
FDA traditional approval is the U.S. Food and Drug Administration’s standard, full marketing authorization pathway granted when a drug has demonstrated substantial evidence of safety and effectiveness through adequate and well-controlled studies.
B. Food and Drug Administration Modernization Act of 1997
The Food and Drug Administration Modernization Act of 1997 is a U.S. law that overhauled FDA regulatory procedures to speed the approval of drugs and medical devices while enhancing patient access to experimental therapies and modernizing agency operations.
C. Food and Drug Administration Amendments Act of 2007
The Food and Drug Administration Amendments Act of 2007 is a U.S. law that expanded the FDA’s authority over drug and device safety, clinical trials, and post-market surveillance, while enhancing transparency and user fee programs.
D. 340B Drug Pricing Program
The 340B Drug Pricing Program is a U.S. federal initiative that requires drug manufacturers to provide outpatient medications to eligible healthcare organizations at significantly reduced prices to support care for underserved patients.
E. Orphan Drug Act of 1983
The Orphan Drug Act of 1983 is a U.S. law that incentivizes the development of treatments for rare diseases by offering benefits such as market exclusivity, tax credits, and research grants to drug manufacturers.
F. None of above. chosen
G. Unsure - the case is ambiguous/there is not enough information to decide.

NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07

Target entity: Abbreviated New Drug Application process
Target entity description: The Abbreviated New Drug Application process is the U.S. regulatory pathway that allows generic drug manufacturers to gain FDA approval by demonstrating bioequivalence to an already approved brand-name drug without repeating full clinical trials.

A. FDA traditional approval
FDA traditional approval is the U.S. Food and Drug Administration’s standard, full marketing authorization pathway granted when a drug has demonstrated substantial evidence of safety and effectiveness through adequate and well-controlled studies.
B. Food and Drug Administration Modernization Act of 1997
The Food and Drug Administration Modernization Act of 1997 is a U.S. law that overhauled FDA regulatory procedures to speed the approval of drugs and medical devices while enhancing patient access to experimental therapies and modernizing agency operations.
C. Food and Drug Administration Amendments Act of 2007
The Food and Drug Administration Amendments Act of 2007 is a U.S. law that expanded the FDA’s authority over drug and device safety, clinical trials, and post-market surveillance, while enhancing transparency and user fee programs.
D. 340B Drug Pricing Program
The 340B Drug Pricing Program is a U.S. federal initiative that requires drug manufacturers to provide outpatient medications to eligible healthcare organizations at significantly reduced prices to support care for underserved patients.
E. Orphan Drug Act of 1983
The Orphan Drug Act of 1983 is a U.S. law that incentivizes the development of treatments for rare diseases by offering benefits such as market exclusivity, tax credits, and research grants to drug manufacturers.
F. None of above. chosen

Statements (49)

Predicate	Object
instanceOf	drug approval process ⓘ regulatory approval pathway ⓘ
administeredBy	FDA Center for Drug Evaluation and Research ⓘ linked to: Center for Drug Evaluation and Research
applicableTo	small-molecule drug products ⓘ
appliesTo	generic drugs ⓘ
associatedWith	Orange Book listings ⓘ
basedOn	Abbreviated New Drug Application ⓘ linked to: Abbreviated New Drug Application process
country	United States ⓘ linked to: United States of America
difference	does not require independent demonstration of clinical efficacy ⓘ relies on prior findings of safety and effectiveness for reference listed drug ⓘ
differsFrom	New Drug Application process ⓘ
documentationForm	electronic common technical document ⓘ
doesNotRequire	full clinical efficacy trials ⓘ independent safety trials equivalent to new drug applications ⓘ
goal	to avoid unnecessary duplication of clinical trials ⓘ to increase availability of lower-cost generic medicines ⓘ
impact	reduces drug costs for patients and payers ⓘ
includesStep	FDA filing review ⓘ bioequivalence assessment ⓘ facility inspection ⓘ final approval or tentative approval decision ⓘ labeling review ⓘ submission of ANDA to FDA ⓘ substantive scientific review ⓘ
involves	patent and exclusivity considerations ⓘ
jurisdiction	Center for Drug Evaluation and Research ⓘ
keyRequirement	demonstration of bioequivalence to a reference listed drug ⓘ
mayResultIn	approval ⓘ complete response letter ⓘ tentative approval ⓘ
notTypicallyUsedFor	biologic products ⓘ
purpose	to provide a pathway for approval of generic versions of previously approved drugs ⓘ
referenceProduct	reference listed drug ⓘ
referenceProductType	previously approved brand-name drug ⓘ
regulatoryAgency	FDA ⓘ linked to: Food and Drug Administration U.S. Food and Drug Administration ⓘ linked to: Food and Drug Administration
regulatoryBasis	Federal Food, Drug, and Cosmetic Act ⓘ
regulatorySection	Section 505(j) of the Federal Food, Drug, and Cosmetic Act ⓘ
relatedTo	New Drug Application process ⓘ
requires	bioequivalence studies ⓘ chemistry, manufacturing, and controls information ⓘ drug product quality data ⓘ good manufacturing practice compliance ⓘ in vitro dissolution data where applicable ⓘ labeling information ⓘ patent certification ⓘ stability data for the drug product ⓘ
shortName	ANDA process ⓘ
supports	generic drug competition ⓘ

How these facts were elicited